Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival. In order to characterize OPD in immunotherapy (IO)-treated NSCLC, we analyzed the failure pattern...

Descripción completa

Detalles Bibliográficos
Autores principales: Rheinheimer, Stephan, Heussel, Claus-Peter, Mayer, Philipp, Gaissmaier, Lena, Bozorgmehr, Farastuk, Winter, Hauke, Herth, Felix J., Muley, Thomas, Liersch, Stephan, Bischoff, Helge, Kriegsmann, Mark, El Shafie, Rami A., Stenzinger, Albrecht, Thomas, Michael, Kauczor, Hans-Ulrich, Christopoulos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226015/
https://www.ncbi.nlm.nih.gov/pubmed/32340408
http://dx.doi.org/10.3390/cancers12041046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226015/
https://www.ncbi.nlm.nih.gov/pubmed/32340408
http://dx.doi.org/10.3390/cancers12041046

Ejemplares similares